Resverlogix Corp.
TSX : RVX

Resverlogix Corp.

July 11, 2005 11:10 ET

Breakthrough in Apo AI Research: Resverlogix Expands NEXVAS Program Into Acute Coronary Market

CALGARY, ALBERTA--(CCNMatthews - July 11, 2005) - Resverlogix Corp. (TSX:RVX) ("Resverlogix"), is pleased to announce that exciting new research has been validated in its lead cardiovascular technology program NEXVAS™. In pre-clinical trials the company has now validated in an animal model a rapid onset of Apo AI enhancement. These findings are novel and will build upon the commercial opportunity of the NEXVAS™ chronic (long term) program and expand the company's presence in the important acute (short term) Cardiovascular Market Segment.

"We are very excited to witness these results at this point in our NEXVAS™ development program," stated Donald J. McCaffrey President and CEO of Resverlogix. "The added benefit of a rapid onset of action of NEXVAS™ accomplishes two critical factors for us; first it expands our commercial opportunity in a very major market segment, Acute Coronary Syndrome, and second it helps expedite the development timeline for NEXVAS™ in the acute market by a couple of years. The range of levels of Apo AI enhancement that we are witnessing in our preliminary trials represent amounts that are greater than those observed in patients in the landmark Apo A1 clinical trial published in JAMA some 18 months ago" McCaffrey further stated. According to the American Heart Association in their 2005 annual report, Coronary Heart Disease accounted for more than $142 billion USD in direct and indirect costs in North America.

"These new findings coupled with our existing chronic effects of NEXVAS™ will provide great synergies to the overall capabilities of NEXVAS™," stated Dr. Jan Johansson. Senior Vice President of Clinical Affairs at Resverlogix. "The ability of our technologies to affect both the acute and chronic setting truly positions us as a leader in the emerging field of Apo AI mediated atherosclerosis stabilization and regression."

The pursuit by Resverlogix of an expanded comprehensive program that will help the entire spectrum of cardiovascular patients is paramount. A core goal of the company is to position itself as a leader in building a cardiovascular franchise for both acute and chronic based vascular management in order to effectively address the grievous burden of CVD globally.

About Resverlogix Corp.

Resverlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, Resverlogix's lead technology NEXVAS™, applies advanced medical research to develop therapies that increase high density lipoprotein (HDL), the "good cholesterol," to treat cardiovascular diseases. The Company's second technology TGF-Beta Shield™ utilizes an immunomodulating approach to target cancers and fibrotic diseases. Resverlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the TSX Exchange under the symbol RVX. For further information, please visit our web site at: www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX does not accept responsibility for the adequacy or accuracy of this news release.

Contact Information

  • Resverlogix Corp.
    Donald J. McCaffrey
    President/CEO
    (403) 254-9252 ext. 223
    (403) 256-8495 (FAX)
    Email: don@resverlogix.com
    or
    Resverlogix Corp.
    Kenneth Lebioda
    Vice President Business Development
    (403) 254-9252 ext. 227
    (403) 256-8495 (FAX)
    Email: ken@resverlogix.com
    Website: www.resverlogix.com